**Supporting Statement Part B**

**The Study to Explore Early Development (SEED)**

**SEED Phase 3**

**OMB #0920-16PA**

**New**

**Laura Schieve, PhD**

**Epidemiologist**

**Centers for Disease Control and Prevention**

**Email: LSchieve@cdc.gov**

**Phone: 404.498.3888**

**Fax: 770.498.1541**

**December 23, 2015**

**Table B.1. GA SEED recruitment indicators: SEED 1 versus SEED 2**

**Table B.2. Sample sizes from SEED 1 and expected from SEED 2**

**Table B.3. Prevalence of select SEED candidate exposures and child health conditions and expected sample sizes**

**Table B.4. Sample size estimates for example ASD case subgroups of etiologic interest**

**Table B.5. Sample size calculations for analyses under various assumptions of exposure prevalence and odds ratio**

**Table B.6. SEED quality control procedures summary**

Supporting Statement B

**Overview**

The overall purpose of the Study to Explore Early Development (SEED) is to investigate risk factors for ASD and symptom subgroups of ASD, using a case-control study design that includes ascertainment of case and comparison groups that represent diverse population subgroups. The objectives of the first funding cycle (2001-2006), subsequently known as SEED 1, were to develop a protocol for a multi-site collaborative epidemiologic study focused on autism (which was eventually named the Study to Explore Early Development [SEED]); to conduct surveillance of autism and other developmental disabilities; and to conduct site-specific investigator-initiated studies on autism. The objectives of the second funding cycle (2006-2011), was implementation of SEED 1. The SEED 1 protocol was reviewed and approved by the OMB, and the OMB No. is 0920-0741. A second phase of SEED (SEED 2) was funded under a third funding cycle (2011-2016); this phase was granted an OMB-PRA clinical research exemption. Five CADDRE grantees received the awards, and CDC served as the sixth SEED 2 site.

The funding and collaborative processes for SEED 3 are similar to those in SEED 1 and 2; CDC funded five extramural sites to conduct SEED 3 (University of Colorado Denver/Anschutz Medical Campus; Johns Hopkins University; University of North Carolina at Chapel Hill; Washington University; and University of Wisconsin, Board of Regents). CDC will also continue to manage the GA SEED site as a sixth site. The six sites will implement the collaborative protocol, and common data elements across all sites will be pooled for analysis. The SEED 3 protocol for identification of study participants, recruitment, and study data collection flow will be the same as the protocols for SEED 1 and 2. No data collection instruments/exams used in SEED 2 will be revised in SEED 3; however, some instruments will not be retained in the protocol to reduce participant burden **(Attachments 5-23)**.

**1. Respondents Universe and Sampling Methods**

SEED is a case control study. Three groups of children and their mothers are enrolled. Case children are those with ASD as determined by the study protocol which relies on developmental assessments administered in a standardized manner by study staff. Two control groups are additionally enrolled: children with other developmental disabilities and delays (DD group) and children from the general population (POP group).

It is expected that the 6 SEED 3 study sites will enroll approximately 3,000 children across the 3 study groups (ASD, DD, and POP) and approximately 2,100 children in all will complete the study protocol. Children must meet all of the SEED eligibility criteria (see **Attachment 4.a**) to be eligible to participate. Assuming a 70% protocol completion rate among enrolled participants, this requires enrollment of ~167 mother-child pairs in each study group (however, it’s important to note that many children who will eventually be classified as an ASD case will initially be identified from data sources as children previously classified as DD because they don’t yet have a ASD diagnosis).

Potential ASD and DD children are cohort children identified by the study as having a suspected ASD or other (non-ASD) developmental delay or disorder (please refer to **Attachment 4.b** for list of diagnoses). Potential ASD and DD children will be identified through sources serving or evaluating children with developmental problems; final ASD case status (i.e., confirmed cases) will be determined from a clinical evaluation using standardized developmental measures conducted as part of the study. Sources for potential ASD and DD children may include, special education programs, state early intervention programs, state autism registries, hospitals, and clinics. POP children will be identified from birth certificates on the basis of birth date range and maternal residence in the catchment area at the time of birth.

***Response Rates***

There are several challenges in accurately determining research response rates for SEED. Because SEED is designed as a case-control study to allow sufficient statistical power to examine risk factors for ASD, children are recruited for participation up to five years post- partum. Additionally, while a key strength of SEED over other epidemiologic ASD studies is the focus on enrolling children from diverse (often understudied) population subgroups, this complicates recruitment procedures as children must be identified from multiple health and education sources at each site. Given the fairly high residential mobility rates of the US population in general and women in the child-bearing age range in particular (Geronimus et al., 2014; Hurley et al., 2005), and the increasing move to cell phones instead of landlines particularly for young adults (Blumberg et al., 2013) it is often challenging to locate individuals identified as potential study participants through tracing procedures.

The above issues render it very difficult to calculate accurate response rates for a study such as SEED where by design eligibility criteria are that participants need to be both born in defined study areas at each site and also continuing to reside in these areas at the time of the study. This latter eligibility requirement is necessary so in person child developmental assessments can be conducted. As mentioned above, those in person assessments are necessary for case classification.

Across sites, we observed the following in SEED 1:

***Mother-child pairs sampled from birth records for POP group***

* Of *potentially* eligible participants sent invitation mailings, study staff had contact with 24%.
* Of those with contact, 34% were found to be ineligible.
* Of those with contact who were found to be eligible, 38% enrolled.

***Mother-child pairs identified from health and school sources for ASD or DD groups***

* Of *potentially* eligible participants sent invitation mailings, study staff had contact with 29%.
* Of those with contact, 26% were found to be ineligible.
* Of those with contact who were found to be eligible, 56% enrolled.

Recognizing that recruitment, and in particular getting participants to respond to the invitation mailings and/or follow-up phone calls made at some SEED sites was one of the greatest study challenges, we added several enhancements and supplements to the SEED 2 recruitment protocol. At all sites, incentives were added for ***all*** ***invited families*** to encourage contact and participation in the eligibility screen even if study participation was refused after the eligibility screen; all sites actively increased outreach activities to make SEED more visible in their communities; some sites enhanced their tracing activities; and the SEED protocol was streamlined and thus less burdensome for participants in SEED 2 compared to SEED 1.

Recruitment response data are still being compiled for SEED 2; however, preliminary data from GA SEED indicate that the enhancements/supplements have had a notable positive effect on our recruitment rates (Table B.1). For mother-child pairs sampled as potential POP participants, both the contact rate and enrollment rate among those eligible were markedly higher in SEED 2. For mother-child pairs sampled as potential ASD or DD participants, the contact rate remained fairly high (>50%) and the enrollment rate among those eligible increased by 59%.

**Table B.1. GA SEED recruitment indicators: SEED 1 versus SEED 2**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **% contact among those invited** | **% ineligible among those contacted** | **% enrolled among those eligible** |
| ***Sampled from birth certificates for POP group*** |  |  |  |
| SEED 1 | 25 | 31 | 28 |
| SEED 2 | 43 | 24 | 58 |
| *% change SEED 2* | *72% increase* | *23% decrease* | *107% increase* |
| ***Identified from school or health sources for ASD/DD group*** |  |  |  |
| SEED 1 | 51 | 20 | 44 |
| SEED 2 | 52 | 22 | 70 |
| *% change SEED 2* | *2% increase* | *10% increase* | *59% increase* |

It is difficult to compare these response rate data from SEED with those from other studies. The vast majority of studies worldwide that examine ASD risk factors have used existing health and administrative databases – for example large health registry linkages in Scandinavian countries and health claims data or health maintenance organization data from select practices in the U.S. While these data have been valuable in providing data on autism risks, they are all limited in terms of both case and exposure ascertainment. Case ascertainment is not standardized; case classification is subject to varying levels of classification bias and data are nearly entirely lacking to construct and examine case subgroups. Exposure/risk factor data are also limited; many important exposures are not included at all, for exposures that are included, many important details are lacking, and exposure data collection processes are not systematic and may be subject to bias. SEED was specifically designed to address these limitations.

To our knowledge there is only one study designed in a similar manner to SEED -- the California Childhood Autism Risks from Genetics and the Environment (CHARGE) study. The CHARGE Study utilized recruitment and data collection methods similar to SEED, however, the CHARGE sample is much smaller -- only 25% that of SEED. Moreover, CHARGE collected data only in the state of California and therefore is less generalizable to a national population. The CHARGE researchers have presented only limited data on participant response rates. No data have been made available on initial contact rates for CHARGE. But the limited data the researchers have presented are comparable to SEED. Specifically, CHARGE investigators state: “Among contacted families of children with autism, 20% were ineligible, 22% refused and 58% agreed to participate. Among general population families with whom we made contact, 22% were ineligible, 41% refused and 36% agreed to join the study.” (Hertz-Picciotto et al., 2006)

In SEED 3 we hope to improve the response rates even further. All sites are asked to work more closely with their data sources to develop mechanisms to increase response to the initial invitation mailing, i.e. through active follow-up via telephone calls, email messages, or both.

***Completion Rates***

In both SEED 1 and SEED 2, study completion rates among participants who enrolled was fairly high. In SEED 1, across sites, 70% of enrolled mother-child pairs progressed through the study to the in person developmental assessment (which is the final data collection step). Preliminary data indicate this proportion will be similar in SEED 2.

## SEED 3 Sample Size Justification

The final sample sizes in each of the study groups (ASD, DD and POP) for SEED 1 and the expected SEED 2 sample sizes for those same groups are presented in Table B.2. Altogether over 1,400 children with ASD are expected to be included in the combined SEED 1 and SEED 2 dataset. The numbers in the DD and POP comparison groups will be slightly higher.

**Table B.2. Sample sizes from SEED 1 and expected from SEED 2**

|  |  |  |  |
| --- | --- | --- | --- |
| **Final Classification** | **SEED 1** | **SEED 2**  **(preliminary)** | **Total SEED 1 + 2** |
| **ASD Group** | 707 | 776 | 1,457 |
| **DD Group** | 995 | 813 | 1,745 |
| **POP Group** | 898 | 760 | 1,658 |

Note: All sample sizes pertain to the number of children who enrolled and completed the study protocol.

We expect this sample to allow us to address many important research questions within our primary and secondary research domains. However, the sample size and corresponding statistical power will not be adequate for many analyses of rare exposures, ASD subtypes, and genetic associations.

Table B.3 provides data on the range of prevalence estimates we expect to observe among the SEED POP group for the types of exposures and child health conditions that will be assessed in SEED; these data are based on past population prevalence estimates. The examples highlighted in the Table illustrate that both rare and common maternal exposures and child health conditions will be examined in SEED.

Table B.4 provides sample size estimates for various types of ASD subgroups of interest. These data highlight that even though we expect to achieve a sample size of >1400 by the end of SEED 2, our sample sizes for some important ASD subgroups might be as low as 300 or less.

Table B.5 presents estimates of sample size needed for analyses based on various scenarios of exposure/health condition prevalence and the strength of the association between ASD (or ASD subtype) and exposure/health condition. All calculations assume 80% power, 5% alpha error, and a 1:1 ratio cases and controls. The odds ratio values used in these calculations – 1.50, 1.75, 2.50, and 3.00 – are based on typical findings from previous studies of various risk factor-ASD associations. The exposure prevalence values used in these calculations match those expected for many maternal exposures and child health conditions being assessed in SEED (see Table B.3). The findings indicate that the combined SEED 1 and SEED 2 sample with >1,400 expected ASD cases will likely be sufficient to examine associations between ASD and very prevalent exposures/health conditions (10% or higher), even when the magnitude of the association is fairly low (OR=1.5). Additionally, the SEED 1+2 sample will be sufficient to examine associations between ASD and exposures/health conditions that are strongly associated with ASD (OR=2.5 or 3.0), even when the prevalence of the exposure/health condition is low (1%). However, the sample size from the first two SEED phases will not be sufficient to examine all exposures with a prevalence of 1–5%, that are more modestly associated with ASD (OR<2.5). Moreover, analyses of associations with ASD subgroups, with much smaller sample sizes than the ASD group overall, will be fairly limited for nearly all studies of SEED 1+2 data.

**Table B.3. Prevalence of select SEED candidate exposures and child health conditions and expected sample sizes.**

|  |  |  |
| --- | --- | --- |
| **POP exposure prevalence estimates** | **Expected number in SEED 1+ 2 ASD group (N=1,483) with exposure or health condition if NO association (null hypothesis is correct)** | **Example exposures and child health conditions included in SEED** |
| 1% | 15 | Assisted reproductive technology use for index pregnancy;  Select maternal chronic conditions such as pre-existing diabetes;  Select child conditions such as epilepsy |
| 2% | 30 | Select maternal infections in pregnancy such as pyelonephritis or sexually transmitted diseases;  Select maternal chronic conditions such as thyroid deficiency. |
| 5% | 74 | Select past infertility conditions such as polycystic ovary syndrome (PCOS);  Use of hormonal infertility treatments (all types combined) for index pregnancy;  Select child health conditions such as asthma |
| 10% | 148 | Any maternal autoimmune condition/allergy (all types combined);  Select child conditions such as ADHD; GI dysfunction in children |
| 20% or more | 297+ | Maternal labor induction or stimulation with Pitocin;  Cesarean delivery;  Maternal fever in pregnancy;  Any maternal infection in pregnancy (all types combined) |

**Table B.4. Sample size estimates for example ASD case subgroups of etiologic interest.**

|  |  |  |
| --- | --- | --- |
| **Proportion of full ASD group** | **Expected number in ASD subgroup for SEED 1 + 2 (based on expected total sample of 1,483 in ASD group)** | **Subgroup** |
| 20% | 297 | Complex autism |
| 30% | 445 | Nonverbal; with regression |
| 40% | 593 | With intellectual disability |
| 60% | 890 | No intellectual disability |
| 70% | 1,038 | Verbal; without regression |
| 80% | 1,186 | Essential autism |

**Table B.5. Sample size calculations for analyses under various assumptions of exposure prevalence and odds ratio.**

|  |  |  |
| --- | --- | --- |
| **Exposure Prevalence (%)** | **Odds Ratio** | **Sample Size Needed in ASD Group or ASD subgroup** |
| 1 | 1.50 | 7,964 |
| 2 | 1.50 | 4,041 |
| 5 | 1.50 | 1,690 |
| 10 | 1.50 | 912 |
|  |  |  |
| 1 | 1.75 | 3,900 |
| 2 | 1.75 | 1,983 |
| 5 | 1.75 | 834 |
| 10 | 1.75 | 454 |
|  |  |  |
| 1 | 2.50 | 1,247 |
| 2 | 2.50 | 637 |
| 5 | 2.50 | 272 |
| 10 | 2.50 | 151 |
|  |  |  |
| 1 | 3.00 | 804 |
| 2 | 3.00 | 413 |
| 5 | 3.00 | 177 |
| 10 | 3.00 | 100 |

All calculations assume 80% power, 5% alpha error, 1:1 ratio cases and controls.

Overall, the expectation is that SEED 3 will add 702 children to the ASD group and each of the two comparison groups. Thus, after SEED 3 we expect to have a sample of 2,106 or more children in the ASD group. This will expand our ability to analyze rare exposures and/or modest (yet scientifically important) associations. For example with the SEED 1+2+3 sample we expect to be better able to assess associations between ASD and maternal exposures/child health conditions in the following scenarios:

* Exposure/health condition prevalence 5% and expected odds ratio 1.50;
* Exposure/health condition prevalence 2% and expected odds ratio 1.75.

Also, we will substantially increase our ability to examine ASD subgroups in depth and to explore potential effect modifications between various ASD risk factors.

**2. Procedures for the Collection of Information**

A complete discussion of SEED 3 sample size estimates including justification for this sample based on statistical power analyses is presented in B.1.

***Data Collection Procedures***

Recruitment and enrollment contact with study participants (mothers of children identified as possible participants for the ASD, DD and POP groups) will consist of: 1) mailed invitation packet via United States Postal Service (USPS) and, 2) follow-up recruitment phone calls and/or emails, (Please see **Attachment 18** for a full study flow chart).

The Invitation Packet **(Attachment 19)** sent via USPS will include:

* + - A letter introducing the study (**Attachment 19.a-c** specific to study group [ASD, DD, or POP]):
    - A study brochure (**Attachment 19.d-f** specific to study group [ASD, DD, or POP]) which provides a brief overview of the purpose of SEED and specific information about the participant activities and incentives.
    - A response card and pre-paid envelope that the invitee can return indicating interest or non-interest in future contact to learn more about the study **(Attachment 19.g).**

Some sites may also use additional invitation materials including incentives valued at ~$1.00**,** and postcards sent in advance of the full Invitation Packet.

To the extent possible, each site will cross check all lists of potential participants against each other in advance of the invitation mailing, such that individuals are not sent duplicate invitations.

If the respondent does not contact the study site within two to six weeks of the invitation mailing (depending on individual site protocols), sites (in concert with their agreements with their data sources) will follow-up with the potential participant. The exact protocol for non-response follow-up will vary by site. At some sites, follow-up phone calls and/or email contacts will be used. At other sites repeat mailings might be included as part of the follow-up protocol. Across sites, a maximum of 9 phone calls/emails will be made in an attempt to follow-up with the potential participant. Telephone calls will be attempted at various times during the day and different days of the week to maximize the potential of contacting participants.

If the potential participant indicates at any point that she is not interested in further contact, no further contact will be attempted. A negative response includes: returning the response card, with “No, I am not interested in learning more about SEED” checked; sending a text or email to the study site indicating that she does not want to be further contacted; calling the study site number and leaving a similar message; indicating to a staff member during a follow-up phone call that she does not wanted to be contacted again.

For those individuals who agree to partake in the enrollment process, the next step is the screening and invitation call. The call will include administration of an eligibility screen (See **Attachment 4.a**. for eligibility criteria), verbal consent for a brief autism screen, the Social Communication Questionnaire (SCQ), and administration of the SCQ.

If the respondent is determined to be ineligible based on answers to the eligibility screen questions, the call will end at this point. The person will be thanked for their time and asked for contact information in order to send the $10 incentive (money order or cash card).

Mothers of children determined to be eligible for SEED will next be administered the SCQ. The SCQ will be administered to mothers of ***all*** children regardless of how they were initially identified (i.e.as potential ASD, DD, or POP participants) (SCQ, **Attachment 5)**. Each child will be assigned to a data collection workflow (ASD, DD, or POP workflow) based on the results of the SCQ screener and whether or not they have a previous diagnosis of ASD. All children with an SCQ score above the threshold set a priori by the study will be considered a presumptive case (even if they do not have a previous diagnosis); additionally, all children with a previous ASD diagnosis at entry into the study will be presumptive cases (even if their SCQ score is below the study threshold).

Presumptive case children (and their mothers) will be assigned to the ASD workflow, which includes 2 in depth standardized autism assessments: (1) direct observation of the child using a standardized scored instrument and (2) an extensive standardized maternal interview which is also scored. The final case classification for these children will be based on the results from these standardized developmental assessments. Children identified as potential DD participants (that is, children who were identified from a clinical or school source has having a non-ASD developmental disability or delay) who screen negative on the SCQ and children identified as potential POP participants who screen negative on the SCQ will be placed in the DD and POP workflows, respectively.

The data collection protocol will vary according to workflow group. In brief, data collection for mother-child pairs in all 3 workflow groups will include, the Pregnancy Reference Form (PRF) questionnaire **(Attachment 7)**, Maternal Interview (MI) **(Attachment 6)**, Maternal Medical History Form **(Attachment 8.a)**, Paternal Medical and Occupational History Form **(Attachment 8.b)**, Child Health History Form **(Attachment 8.c)**, and the Maternal and Child Residential History Form **(Attachment 8.d)**. The data collection protocol for the DD group will end upon completion of these instruments. The POP and ASD workflow data collection protocols will both additionally include the Child Behavior Checklist (CBCL) **(Attachment 8.e)**, child Social Responsiveness Scale (SRS) **(Attachment 8.f-g)**, an in person developmental assessment **(Attachment 9)**, collection of maternal, paternal, and child saliva specimens and maternal and child blood specimens **(Attachments 16-17)**, and maternal and child anthropometry measurements **(Attachment 16.a)**. Although both the ASD and POP workflow protocols will include an in person assessment, it will be more extensive for the ASD than POP workflow. Children in both the POP and ASD workflows will be administered the Mullen Scales of Early Learning **(Attachment 9.a)**. Children in the ASD workflows will be additionally be administered the Autism Diagnostic Observation Scales (ADOS) **(Attachments 9.d-f)** and their mothers will be administered the Autism Diagnostic Interview (ADI-r) **(Attachment 9.g)**, the Vineland Adaptive Behavior Scales (VABS) **(Attachment 9.b)** and the Services and Treatment Questionnaire **(Attachment 8.h)**. The ordering, mode of administration, and other relevant field activities for each of these instruments is described below.

Upon completion of the Invitation and Screening call, the Enrollment Packet **(Attachment 20)** will be mailed to participants. This packet will include a cover letter **(Attachment 20.a-b** specific to workflow [ASD, DD, or POP]), a participant-friendly study flow diagram **(Attachment 18),** consent document to review (**Attachment 11.a-c** specific to workflow [ASD, DD, or POP]), the study “Bill of Rights” **(Attachment 20.c),** and one money order incentive totaling $10 (as promised during the screening and invitation call).

As part of the subject recruitment and retention process, study sites will maintain a record of written and telephone contacts with invitees and subjects. Once a family is enrolled, each site will track the family’s completion of data collection steps and receipt of incentives using tracking software created by the Data Coordinating Center (DCC).

At least one week after the Enrollment Packet has been mailed, study staff will phone the participant to answer any initial questions about the study and the enrollment packet materials and to complete the Pregnancy Reference Form (PRF) questionnaire **(Attachment 7.b)** (Note; some sites might opt to administer the PRF questionnaire at the end of the Invitation and Screening call, depending on participant availability). The PRF questionnaire is a very brief instrument that ascertains information on the index pregnancy timing that will be referenced during the Maternal Interview (MI); thus, the PRF questionnaire must be completed in advance of the MI.

Once the PRF questionnaire is completed, the participant is informed that the pregnancy calendar, the Maternal Interview Preparatory Guide **(Attachment 6.c)** and a $20 money order or cash card for completing the call will be mailed in advance of the interview.

The MI will be administered via telephone with a Computer-Assisted Telephone Interview (CATI) and will take approximately 45 minutes to complete. Interviews may also be conducted face-to-face for Spanish-only speaking participants. In these cases, a hard copy of the interview will be used initially, and information will be transferred to the electronic database. Once the MI is complete, the participant will be informed that a packet of checklist-type forms plus a $45 money order or cash card for completing the MI will be mailed to her next. For participants in the ASD and POP workflows, the in-person clinic visit might also be scheduled at the end of the MI call. The entire phone call may take 60 minutes (45 minute Maternal Interview and 15 minute discussion of next steps and scheduling).

For all 3 workflow groups, the forms packet mailed to the mother will include:

* Maternal Medical History Form **(Attachment 8.a)** – estimated time to complete 10 minutes.
* Paternal Medical and Occupational History Form **(Attachment 8.b)** – estimated time to complete 10 minutes.
* Child Health History Form **(Attachment 8.c)** – estimated time to complete 30 minutes.
* Maternal and Child Residential History form **(Attachment 8.d)** – estimated time to complete 5 minutes.

For the for the ASD and POP workflows, the packet will also include 2 standardized developmental assessments:

* Child Behavior Checklist (CBCL) **(Attachment 8.e)** – estimated time to complete 20 minutes.
* Social Responsiveness Scale (SRS) (**Attachment 8.f-g** specific to age) – estimated time to complete 20 minutes.

All of the above forms are designed to be self/parent administered. However, at all sites, staff will work with participants to complete the forms for them over the phone if preferred.

In addition to the foregoing forms, this packet will also include materials to assist the mothers and children in the ASD and POP workflows to prepare for the upcoming clinic visit:

* Frequently Asked Questions on Biosampling **(Attachment 15.a)**
* Picture Story **(Attachment 15.b)** with child friendly descriptions of each event in which the child will participate.
* Clinic Visit Prep Guide with more detailed information for the mother (**Attachment 15.c-d** specific to workflow ASD or POP)

If the forms are not returned via mail and/or if the participant indicates she prefers to complete the forms with assistance, SEED study staff will telephone the participants. Additionally, even for forms that were completed and mailed to the SEED site, study staff will review any ambiguous or illegible responses during a follow-up phone call. For mothers in the ASD and POP workflows, the follow-up call will also include a review of the materials sent on how to prepare for the in person visit and a discussion of what to expect during that visit.

Once the forms in the packet are completed, the data collection for DD workflow participants is complete. Mothers in this group will be mailed a thank you letter and $50 for the time spent completing the forms.

The last step of the data collection protocol for in the POP and ASD workflow groups is the in person visit. For POP participants the visit will last approximately 1 hour and 10 minutes. For ASD workflow participants the visit will last approximately 5.5 hours. NOTE: for both groups, the time might be longer if the participant has not yet completed all forms from the previous step. The visit will include four main components: answer questions and obtain written informed consent (20 minutes); complete any forms from the forms packet which have not yet been returned and sign the pre-filled medical release forms (time varies and sites will strive to have nearly all of the forms completed in advance of the in-person visit – see above description of follow-up phone call); conduct developmental evaluation (50 minutes for POP workflow; 270 minutes for ASD workflow); anthropometry and collect saliva and blood samples (40 minutes). The mother will also be provided with the final study incentives during this visit - $50 for completion of the forms packet and $75 or $200 for the visit depending on whether the child is in the POP or ASD workflow.

The visits will take place at predetermined locations at each of the study sites. At some study sites this may include participants’ homes.

The developmental assessment will begin once the child appears comfortable with the diagnostician and staff. Parents will be encouraged initially to sit with the child during the assessment in order to make him/her more comfortable. Children will be able to take a break if needed. If for any reason the child cannot complete the assessment, the family will be encouraged to schedule another appointment to complete the evaluation.

The measures administered during the child developmental assessment are listed below. Copies of the score sheets for each of the measures can be found in **Attachment 9.**

* Mullen Scales of Early Learning (MSEL, POP and ASD workflows) (**Attachment 9.a**): standardized assessment with the child that assesses cognition in five developmental domains, Takes an average of 50 minutes to administer.
* Vineland Adaptive Behavior Scales (VABS, ASD workflow) (**Attachment 9.b-c**) Interview with mother that includes items on child’s communication, daily living skills, socialization, and motor domains. Takes an average of 45 minutes to complete.
* Autism Diagnostic Observation Scale (ADOS, ASD workflow) (**Attachment 9.d-f**): a standardized instrument in which the researcher observes the child and tries to illicit social interaction and communication through the use of structured play activities. The examiner implements the module that best corresponds to the child’s expressive language level in order to prevent language aptitude from impeding accurate diagnosis. Takes an average of 45 minutes to complete and generates data that are scored to determine final study group classification – ASD case or control.
* Autism Diagnostic Interview (ADI-R, ASD workflow) (**Attachment 9.g**) a semi-structured interview with the mother that includes questions about child’s current and past social and communicative behaviors. Takes an average of 120 minutes to complete and generates data that are scored to determine final study group classification – ASD case or control.
* Services and Treatment Questionnaire (ASD workflow) (**Attachment 8.h**) Captures information related to the child’s current use of developmental services. Takes approximately 10 minutes to complete.

With appropriate consent, at least 10% of the overall sample of children who receive the full developmental evaluation will have the ADI-R and ADOS and/or Mullen and Vineland videotaped for quality control purposes. All data from the developmental assessment is recorded on hard-copy record forms that will subsequently be transferred into an electronic database.

After completion of the developmental evaluation, a qualified examiner will take height, weight and head circumference measurements of the child and height and head circumference measurement of the mother (both POP and ASD workflows). The examiner will also ask the mother if the child has ever been diagnosed or been examined for a major birth defect or genetic syndrome (**Attachment 16.a**).

Saliva samples from all children in the ASD and POP workflows, their biological mothers and if available and willing their biological fathers will be collected. We anticipate compliance using this approach will be higher than blood sampling, because of the greater convenience and less discomfort to the participant. Also, in some instances, a blood draw attempt may fail. Unfortunately, saliva samples potentially yield less DNA, or a lower quality sample of DNA than blood. Collecting saliva samples will ensure that genetic material is obtained on a greater number of participants, while blood samples will ensure a higher quality sample of DNA.

If the biological father lives in the child’s household and is not available for the clinic visit, but is willing to provide a saliva sample, then the father’s saliva collection kit will be given to the biological mother at the clinic visit. Likewise, biological fathers not living with the mother and child may be mailed a saliva collection kit if they are willing to provide a specimen. Contents of the saliva collection kit are described in **Attachment 16.b-d**.

Venous blood sampling will be collected on children and biologic mothers in the ASD and POP workflows. Mothers will be asked to complete for herself and for the child a brief checklist of recent exposures that might affect blood analyses (e.g., medications, illnesses) (**Attachment 17.a-b**). Blood draws on children will be conducted at the end of the visit by protocol-trained study phlebotomists having prior pediatric blood draw experience. Other staff and the mother will be present to assist with restraint, distraction, and reinforcement. No more than two attempts will be made to complete the draw during any clinic visit. Study staff may offer mothers the option that children receive a local topical anesthetic prior to venipuncture. However, the mother will make the final decision as to whether the anesthesia cream is used. A maximum of 13mL of blood will be collected using vacutainers appropriate for pediatric draw volumes. Optional residual blood in the butterfly tube (less than 1mL) will be used for the filter paper blood spots. Federal guidelines prohibit the draw of more than 3mL/kg body weight per eight-week period. Consequently, a child would only have to weigh about 4.33 kg (9.5 lbs) to be eligible to provide this amount of blood.

***Training and Quality Control of Data Collection Activities***

For each data collection instrument, staff training and quality control procedures have been developed. All staff members will receive a general overview training with a standardized training protocol and instruction manual. Each staff member will receive additional training with respect to the specific data collection components for which they will be responsible. Additionally, both initial and ongoing quality control procedures have been developed for each data collection activity. A summary of the quality control requirements for each study instrument is presented in Table B.6.

**Table B.6. SEED quality control procedures summary**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study contacts and instruments** | **Type of QC assessment(s) and requirements** | **Specific QC training requirements1** | **Ongoing QC requirements (frequency of QC)** |
| Invitation phone call, including eligibility screener and Social Communication Questionnaire | *Intra-site:* Semi-qualitative call rating form -- a priori criteria established for acceptable score.2 | Acceptable scores on 3 role playing (mock) calls and first 2 “live” calls. | 5% per interviewer |
| Follow-up call, including structured Pregnancy Reference Form interview | *Intra-site:* Semi-qualitative call rating form -- a priori criteria established for acceptable score.2 | Acceptable scores on 3 role playing (mock) calls. | 5% per interviewer |
| Maternal Interview | *Intra-site:*  1) Semi-qualitative call rating form -- a priori criteria established for acceptable score.2  2) Quantitative inter-rater reliability assessment of selected interview items. Acceptable score is >95% concordance. | Acceptable scores for both assessments on 3 role playing (mock) interviews and first 2 “live” calls. | 5% per interviewer |
| Parent/self-administered forms3  (forms sometimes administered by SEED study staff via phone or in person) | No specific systematic QC requirements, but continual supervisor oversight and all forms reviewed for missing or illegible data or contradictory entries. Participants are re-contacted as needed. | None. General training provided on forms and appropriate responses to participant queries. | NA |
| Autism Diagnostic Observation Schedule (ADOS) | *Inter-site:* supervising clinicians establish reliability by scoring the same ADOS exam videotapes. Acceptable score is >80% concordance on algorithm items.  *Intra-site:* all clinicians establish reliability with supervising clinician. Acceptable score is >80% concordance on algorithm items. | Both inter-site and intra-site reliability established in advance of study start. | quarterly inter-site and intra-site reliability exercises |
| Autism Diagnostic Interview - revised (ADI-r) | *Inter-site:* supervising clinicians establish reliability by scoring the same ADI-r interview videotapes. Acceptable score is >90% concordance on algorithm items.  *Intra-site:* all clinicians establish reliability with supervising clinician. Acceptable score is >90% concordance on algorithm items. | Both inter-site and intra-site reliability established in advance of study start. | quarterly inter-site and intra-site reliability exercises. |
| Mullen Scales of Early Learning | No specific systematic QC requirements, but continual supervisor oversight and all forms reviewed for missing or illegible data or contradictory entries. | None. Supervising site clinicians monitor initial assessments until competency determined. | NA |
| Vineland Adaptive Behavioral Scales | No specific systematic QC requirements, but continual supervisor oversight and all forms reviewed for missing or illegible data or contradictory entries. | None. Supervising site clinicians monitor initial assessments until competency determined. | NA |
| Anthropometrics: Height, weight, and head circumference | *Intra-site:* All examiners establish reliability with project coordinator or other qualified examiner on age appropriate individuals.  Acceptable reliability defined as agreement in 95% of instances (agreement within 0.5 cm for height and head circumference and 0.1kg in weight).  Equipment calibrated periodically as needed. | Acceptable measurements on 5 role play (mock) individuals and on first 2 participants. | 5% per examiner |
| Biologic specimens:  Saliva specimens (child, mother and father if available) and blood specimens (child and mother)  (ASD and POP workflow only) | *All*: central lab staff processes specimens upon receipt and performs preliminary QC (gross visual inspection).  *Sample of mothers:* second blood specimen obtained for duplicate processing and analysis | None. Extensive staff training on study protocol for obtaining and processing biologic specimens | 2% sample of duplicate blood specimens |

1 Training QC requirements include requirement for staff to pass formal reliability or other QC assessment on mock exercises in advance of "live" field work and initial QC requirement on first instruments/exams once in the field. For each instrument, if a study staff member does not meet criteria for acceptable score during ongoing QC, retraining and training QC requirements are instituted.

2 Semi-qualitative call rating forms for invitation, follow-up, and maternal interview calls include items such as use of call script, coverage of essential points, ability to respond to participant questions, probing on unclear or neutral responses, professionalism, and delivery and response recording for applicable study instruments (Social Communications Questionnaire, Pregnancy Reference Form, or Maternal Interview). For each item, QC supervisor rates interviewer as “good”, “fair” or “poor”. Criteria for acceptable score include: no item rated as “poor” and 20% or less rated as “fair”; and mandatory ratings of “good” for select items (dependent on call type).

3 Parent/self-administered forms include Maternal Medical History Form, Paternal Medical and Occupational History Form, Child Health History Form, Maternal and Child Residence History Form, Child Behavior Checklist (ASD and POP workflows only), Child Social Responsiveness Scale (ASD and POP workflows only), Child Services and Treatments Questionnaire (ASD workflow only).

**3. Methods to Maximize Response Rates and Deal with No Response**

## In the preceding sections (B.1 and B.2) we described barriers to recruitment, response rates from SEED 1 and SEED 2, comparisons to response data from other ASD risk factor studies, and our procedures for following up with participants we fail to reach after the initial invitation mailing. Here we describe our analyses of non-response bias and revisions to the SEED 3 protocol to enhance response rates and better assess non-response.

***Analyses of Non-Response in Previous Phase of SEED***

## We assessed potential non-response bias both theoretically and empirically. As in most research studies that require active consent, there is a possibility that the study participants will not be representative of the population. We reviewed key articles on non-response effects. In a case-control study, differential participation between case children and control children can potentially lead to biased results. However, as noted by Bartlett et al. (2015), “…logistic regression complete records analysis can provide asymptotically unbiased estimates of the association of an exposure of interest with an outcome, adjusted for a number of confounders, under a surprisingly wide range of missing-data assumptions…. Specifically, exposure odds ratios are estimated without bias (asymptotically) provided that missingness does not depend jointly on exposure and outcome, and even then, special cases exist where bias does not result.” Based on this well-grounded theoretical framework for nonresponse bias, we conducted empirical analyses to better understand which factors were and were not associated with non-response.

Most SEED sites were not able to gather detailed information about non-responders. However, GA SEED has access to birth certificate data on all mother-child pairs sent an invitation packet whether or not they were contacted and whether or not they enrolled in SEED once contacted. These birth certificate data included several demographic factors and several perinatal factors. We conducted a series of analyses to better understand how non-response using the SEED data collection protocol might impact results from subsequent analyses of SEED data. Key findings from our assessment are summarized as follows:

* 3 demographic factors were associated with non-response in POP group:  maternal race-ethnicity, maternal age, and maternal education.
* 2 of these factors - maternal age and education - were associated with non-response in the ASD group.
* None of the perinatal risk factors we examined – preterm delivery, very preterm delivery, Cesarean delivery, induction of labor – were associated nonresponse in either the POP or ASD groups.
* We estimated odds ratios for associations between ASD and each of the aforementioned perinatal risk factors in 2 samples: our final sample (i.e. complete case analysis) and the full GA SEED sample of invited participants. We found that both unadjusted and adjusted odds ratios were similar across the two samples. This indicates that analyses of these types of factors using our final study sample are not biased.
* To further explore factors not available on the birth certificate, we created sampling weights whereby we weighted the final sample to more closely match the initial invited sample in terms of maternal demographics. We then performed weighted and unweighted analyses for associations between ASD and several maternal factors ascertained from the maternal interview, such as maternal infertility. Our estimates from weighted analyses matched well with the estimates from the unweighted analyses. This again indicates that these types of risk factor analyses are not biased in SEED.

In sum, using GA SEED data we demonstrated empirically that while select demographic factors were directly associated with study response, other biologic factors were not. Moreover, we demonstrated that analyses of associations of such biologic factors – both perinatal factors on the birth certificate and preconception health history factors captured via maternal interview – were not impacted by the low SEED 1 response rates.

***SEED 3 Enhancements***

We have added several enhancements to the SEED 3 protocol to further address recruitment issues and our ability to assess response impacts. In SEED Phase 3 all sites are asked to work more closely with their data sources to develop mechanisms to increase response to the initial invitation mailing, i.e. through active follow-up via telephone calls, email messages, or both. Additionally, in SEED 3, sites are asked to develop a mechanism a priori to obtain necessary permissions to allow for linkage of birth certificate data on ***all*** participants (ASD, DD, and POP groups) invited including those who are never successfully contacted, those who refuse contact, and those contacted but found to be ineligible such that SEED investigators will be able to directly assess characteristics of respondents vs. non-respondents. Thus, SEED 3 data will be invaluable not only in increasing the SEED sample which will allow investigators to conduct detailed analyses of ASD risk factors and the health of children impacted by ASD, but also in providing an unprecedented opportunity to understand response impacts not only in SEED analyses but in many case control analyses of ASD, for which there is currently a clear dearth of data.

**4. Tests of Procedures or Methods to be Undertaken**

In SEED 1, several standardized developmental assessment instruments were used that were previously developed and assessed for reliability by other groups; we carefully reviewed the data from those past instrument assessments and chose instruments that were both shown to be valid and reliable and best fit our study objectives. We also developed several study instruments such as the maternal interview, and many of the parent/self-administered forms. In constructing these forms we used questions previously developed and tested in other studies when feasible.

All instruments developed as part of the SEED 1 protocol were also pilot tested on small numbers of mother-child pairs who met the eligibility criteria for participation in SEED (<9) to detect ambiguous questions. Moreover, during staff training and project planning at each site, multiple mock (role-playing) exercises were conducted to develop efficient processes for data collection and identify any gaps or problem areas. During these exercises, further question verbiage problems were sometimes identified (often we asked the individuals acting as mock participants in role playing exercises to be challenging by asking difficult questions and creating scenarios in which they had complex reproductive histories). Additionally, as previously mentioned, we established very comprehensive quality control standards for all data collection components of SEED 1 and upon initiation of field work we carefully monitored data collection practices and made some adjustments early in the study.

This careful planning was essential to ensuring we were collecting high quality data; nonetheless, by the end of SEED 1, we became aware of a few questions that didn’t work well and a few instruments that needed to be revised. We also sought to streamline data collection in SEED 2; this involved dropping some instruments altogether and consolidating others. Before beginning field work for SEED 2 we again conducted a few very small pilot tests of select instruments and again had study staff go through extensive training and mock data collection exercises. We again made a few revisions based on issues identified before field work was initiated.

In SEED 3 we have eliminated two instruments altogether from the data collection protocol. All other instruments will be retained without revision in order to ensure efficient data harmonization. During SEED 2 data collection, quality control exercises and ongoing general monitoring conducted at all sites indicated that all study instruments worked well.

**5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or**

**Analyzing Data**

SEED is a collaborative effort between the CDC, NCBDDD and the extramural CADDRE Centers (Note: CADDRE is the consortium of Centers for Autism and Developmental Disabilities Research and Epidemiology, these are the sites funded to conduct SEED). NCBDDD is also supported through contracts with Research Triangle Institute (RTI) International, Maximus Federal, and Carter Consulting, Inc. Staff members in NCBDDD involved in SEED include the following:

* Laura Schieve is the Team Lead, Epidemiology Team, DD Branch and the Science Lead for the CADDRE Network (also known as the “CADDRE PI”). Dr. Schieve is responsible for scientific oversight of the CADDRE sites and SEED project activities overall, providing direction to the collaboration. Dr. Schieve also currently serves as a co-PI for the CDC site – GA SEED.
* Seema Gupta serves as Project Coordinator of CADDRE activities
* Lucinda England is the CDC Science Lead for the CADDRE-SEED Data Coordinating Center [located at Michigan State University and funded through a separate cooperative agreement] and GA SEED co-investigator
* Aimee Alexander is the CADDRE-SEED Data Coordinator and Biomarker Analysis and Laboratory Coordinator
* Lisa Wiggins is the CADDRE lead clinician and GA SEED co-PI and supervising site clinician
* Matthew Maenner is the GA SEED PI
* Charmaine McKenzie is the GA SEED Project Coordinator
* Stuart Shapira is a GA SEED co-investigator
* Nicole Dowling is a GA SEED co-investigator

The PIs during SEED 1 and 2 were (see **Attachment 13**):

**Laura Schieve, Ph.D.**

Centers for Disease Control and Prevention

(404) 498-3888

Email: LSchieve@cdc.gov

**Lisa Croen, Ph.D.**

Kaiser Permanente Division of Research

Phone: (510) 891-3463  
Email: [Lisa.A.Croen@kp.org](mailto:Lisa.A.Croen@kp.org)

**Gayle C. Windham, PhD**

Division of Environmental and Occupational Disease Control

CA Department of Public Health

Phone: 510-620-3638

Email: [Gayle.Windham@cdph.ca.gov](mailto:Gayle.Windham@cdph.ca.gov)

**M. Daniele Fallin, Ph.D.**

Johns Hopkins University, Bloomberg School of Public Health

Phone: (410) 955-3463

Email: [dfallin@jhsph.edu](mailto:dfallin@jhsph.edu)

**Jennifer Pinto-Martin, Ph.D., MPH,**

University of Pennsylvania, School of Nursing

Phone: (215) 898-4726

Email: [pinto@nursing.upenn.edu](mailto:pinto@nursing.upenn.edu)

**Susan Levy, M.D.**

Division of Child Development and Rehabilitation  
Children's Seashore House of The Children's Hospital of Philadelphia  
Telephone 215 590-7528  
levys@email.chop.edu

**Julie Daniels, Ph.D.**

University of North Carolina at Chapel Hill

School of Public Health

Phone: (919) 966-7096

Email: [Julie\_daniels@unc.edu](mailto:Julie_daniels@unc.edu)

**Cordelia Robinson (Corry), Ph.D., R.N.**

JFK Partners/UCHSC

Phone: (303) 864-5261

Email: [robinson.cordelia@tchden.org](mailto:robinson.cordelia@tchden.org)

NCBDDD also funded a Data Coordinating Center (DCC) and a Central Laboratory and Biosample Repository (CLBR) for SEED. Michigan State University established and manages the Data Coordinating Center and Johns Hopkins University houses the CLBR for SEED 1 and SEED 2. Both a DCC and CLBR will again be funded for SEED 3 activities.

All SEED principal investigators worked collaboratively to develop the original SEED protocol. Multiple working groups were established to organize and develop this large and multi-faceted case-control study.

In addition to the working groups, some of the original SEED sites (California, Pennsylvania, and Maryland) had advisory boards, including parents of children with autism, to review the original study materials and the study design. The SEED sites also conducted focus groups during the original planning phase and planning for SEED 2 with parents of children with and without developmental disabilities. The purpose of the focus groups was to obtain additional feedback on the study design and feasibility of the study.

Additionally, CDC, along with the CADDRE partners, established a five person peer review panel during the original study design phase. This panel consisted of experts in clinical research, epidemiology, genetics, immunology, and advocacy (see **Attachment 14**). Each of the panel members reviewed the SEED protocol and appendices and provided feedback to the CADDRE group. The CADDRE PIs identified changes that were required of the protocol based on the panel’s feedback and these changes were incorporated into the protocol prior to submission to the IRB. Also, in preparation for SEED Phase 2, CDC invited a panel of outside experts in epidemiology and population-based research field methods to review the SEED Phase 1 recruitment and enrollment methods and provide recommendations for improvement. These recommendations were incorporated into the SEED Phase 2 methods.

In SEED 3, CDC funded five sites through open competition. Three of the sites (University of Colorado/Anshutz Medical Campus; Johns Hopkins University; University of North Carolina at Chapel Hill) had been included in SEED 1 and 2 and the PIs remained the same. Two new sites were funded (Washington University; University of Wisconsin, Board of Regents). The SEED 3 PIs will work together in a manner similar to the SEED 1 and 2 PIs on all aspects of study implementation and data analysis.

The PIs for SEED 3 are:

**M. Daniele Fallin, Ph.D.**

Johns Hopkins University, Bloomberg School of Public Health

Phone: (410) 955-3463

Email: [dfallin@jhsph.edu](mailto:dfallin@jhsph.edu)

**Julie Daniels, Ph.D.**

University of North Carolina at Chapel Hill

School of Public Health

Phone: (919) 966-7096

Email: [Julie\_daniels@unc.edu](mailto:Julie_daniels@unc.edu)

**Cordelia Robinson (Corry), Ph.D., R.N.**

JFK Partners/UCHSC

Phone: (303) 864-5261

Email: [robinson.cordelia@tchden.org](mailto:robinson.cordelia@tchden.org)

**John Constantino, M.D.**

Washington University

School of Medicine in St. Louis

Phone: (314) 747-6772

Email: constantino@wustl.edu

**Maureen Durkin, Ph.D., Dr.P.H.**

University of Wisconsin

School of Medicine and Public Health

Phone: (608) 263-7507

Email: [mdurkin@wisc.edu](mailto:mdurkin@wisc.edu)

**Matthew Maenner Ph.D.**

Centers for Disease Control and Prevention

(404) 498-3888

Email: [MMaenner@cdc.gov](mailto:MMaenner@cdc.gov)

**Laura Schieve, Ph.D.**

Centers for Disease Control and Prevention

(404) 498-3888

Email: LSchieve@cdc.gov